Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Catalent Inc (CTLT)

Catalent Inc (CTLT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,848,147
  • Shares Outstanding, K 154,898
  • Annual Sales, $ 2,518 M
  • Annual Income, $ 137,400 K
  • 60-Month Beta 1.64
  • Price/Sales 4.83
  • Price/Cash Flow 23.74
  • Price/Book 5.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.59
  • Number of Estimates 4
  • High Estimate 0.65
  • Low Estimate 0.54
  • Prior Year 0.65
  • Growth Rate Est. (year over year) -9.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.51 +17.57%
on 04/28/20
80.52 -8.73%
on 05/26/20
+10.27 (+16.24%)
since 04/27/20
3-Month
31.04 +136.76%
on 03/18/20
80.52 -8.73%
on 05/26/20
+21.04 (+40.11%)
since 02/27/20
52-Week
31.04 +136.76%
on 03/18/20
80.52 -8.73%
on 05/26/20
+27.26 (+58.97%)
since 05/24/19

Most Recent Stories

More News
% (CTLT)

SmarTrend identified a Downtrend for Catalent Inc (NYSE:CTLT) on March 25th, 2020 at $47.96. In approximately 2 months, Catalent Inc has returned 60.09% as of today's recent price of $76.77.

CTLT : 73.49 (-3.92%)
Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

XPH : 43.22 (+0.63%)
JNJ : 144.89 (+0.23%)
LLY : 145.70 (-1.53%)
CTLT : 73.49 (-3.92%)
PJP : 63.71 (+0.60%)
IHE : 154.78 (+0.66%)
Catalent Inc Set to Possibly Pullback After Yesterday's Rally of 2.31%

Catalent Inc (NYSE:CTLT) traded in a range yesterday that spanned from a low of $71.96 to a high of $73.64. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $73.40...

CTLT : 73.49 (-3.92%)
Catalent, Inc. to Present at May 2020 Virtual Investor Conferences

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products,...

CTLT : 73.49 (-3.92%)
Catalent Inc (CTLT)

SmarTrend identified a Downtrend for Catalent Inc (NYSE:CTLT) on March 25th, 2020 at $47.96. In approximately 1 month, Catalent Inc has returned 41.16% as of today's recent price of $67.70.

CTLT : 73.49 (-3.92%)
Catalent (CTLT) Q3 Earnings and Revenues Beat Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 2.04% and 10.18%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CTLT : 73.49 (-3.92%)
Catalent: Fiscal 3Q Earnings Snapshot

SOMERSET, N.J. (AP) _ Catalent Inc. (CTLT) on Tuesday reported fiscal third-quarter earnings of $20.9 million.

CTLT : 73.49 (-3.92%)
Catalent, Inc. Reports Third Quarter Fiscal 2020 Results

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products,...

CTLT : 73.49 (-3.92%)
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

Arcturus Therapeutics Holdings Inc. ("Arcturus", "the Company", Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc. (NYSE: CTLT), the leading...

CTLT : 73.49 (-3.92%)
ARCT : 38.56 (-28.99%)
Catalent Announces Next Generation of Cell & Gene Therapy Leadership

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products,...

CTLT : 73.49 (-3.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CTLT with:

Business Summary

Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the...

See More

Key Turning Points

2nd Resistance Point 78.82
1st Resistance Point 76.15
Last Price 73.49
1st Support Level 71.59
2nd Support Level 69.70

See More

52-Week High 80.52
Last Price 73.49
Fibonacci 61.8% 61.62
Fibonacci 50% 55.78
Fibonacci 38.2% 49.94
52-Week Low 31.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar